It is a medicine “are of major therapeutic interest”, according to the terms of the decree adopted in 2016 to avoid the risk of shortage, which is today in short supply
Sinemet, a treatment mainstay in the management of patients of Parkinson’s, is no longer available in dosage 250 mg since the end of August, and its other two forms (100 mg and 200 mg extended release) will soon be delivered in pharmacies, announced the national security Agency of the drug (MSNA) on September 19. According to the laboratory MSD, which refers to “production difficulties”, a replenishment is not expected until march 2019. The prospect of a stock shortage has caused outrage from patients ‘ associations. “For the second year in a row, and this time for a duration of a particularly long, patients and their families find themselves in a situation of insecurity.
This generates a huge stress,” says Florence Delamoye, director of the association France Parkinson. The scenario of a shortage worried the doctors that the withdrawal of Levodopa can prove to be dangerous According to the MSNA, the 45,000 patients are treated by Sinemet, about 200,000 people suffering from Parkinson’s disease in France. The treatment based on Levodopa, compensates for the deficit of dopamine in the brain that characterizes the disease. It strongly improves the symptoms: slowness and stiffness which lead to a difficulty with gestures or discomfort in walking, tremors. “All patients will be required to take a drug-based Levodopa at one time or another of their illness, says the Pr Philippe Damier, a neurologist at the CHU of Nantes. Fifty years after his arrival in the provision of care, it is still the basic treatment. “The scenario of a shortage worried the doctors that the withdrawal of Levodopa can be dangerous. “A sudden stop can lead to complications are potentially severe, up to death,” warns the Pr checker board. In a note published on its website, the MSNA recommends that patients consult with their doctor to find a treatment of substitution. Neurologists can, in theory, see their prescription on the generic of Sinemet, but the laboratory Teva, which produces one of them, has already warned that it will not be able to cope with the demand alone.
An alternative Solution, the Modopar, a drug combining Levodopa with another molecule, may be proposed. “This change may only occur after a dose adjustment, and only if the patient has no previous history of intolerance major,” says Dr. . Philip Vella, director of medicine in neurology at the MAN. The Roche laboratory, that produces the Modopar, is committed to the Agency to manufacture it in sufficient quantity to cover the needs of the sick until at least December.
The association France Parkinson’s fears, however, that the change of molecule would destabilise patients who are already weakened by a disease that knows no cure, but for which the disabling symptoms can be relieved by the treatments. . .